NSCLC
Conditions
Interventions
Advanced non small cell lung cancer patients who failed first-line treatment with PD-1/PD-L1 inhibitors:Non-intervention
Sponsors
Lankao County First Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) , male or female patients aged 18-75; (2)?ECOG PS 0-1; (3) , patients with locally advanced and/or metastatic stage IIIB, IIIC or IV (according to the 8th edition of the United States Joint Commission on Cancer Lung Cancer Staging System) NSCLC who have previously failed to receive first-line PD-1/PD-L1 inhibitor treatment, confirmed by histology or cytology and cannot undergo radical synchronous radiotherapy and chemotherapy. ? Definition of treatment failure: a Proven disease progression occurred during the treatment of PD-1/PD-L1 inhibitor or after the last treatment; B. Withdrawal due to intolerance of adverse events or unwillingness to continue treatment; C. For subjects who have previously received PD-1/PD-L1 inhibitor synchronous or sequential chemotherapy, synchronous or sequential radiochemotherapy, if relapse/metastasis occurs within 6 months after the last treatment, the original treatment plan is defined as the first-line treatment plan for the subject. (4) All patients should be EGFR/ALK/ROS1 wild type; (5) There is at least one target lesion that has not received radiotherapy in the past six months, and can be accurately measured in at least one direction by magnetic resonance imaging (MRI) or computed tomography (CT), with its maximum diameter = 10 mm;
Exclusion criteria
Exclusion criteria: (1) . Patients who have previously used anlotinib hydrochloride capsules or other anti-angiogenic drugs, or who have been judged by the researcher to be unsuitable for the use of anti-angiogenic drugs. (2) , patients with anltinib and contraindications to immunotherapy. (3) . Patients whose adverse reactions (excluding hair loss) related to anti-tumor treatment after previous systemic anti-tumor treatment have not recovered to NCI-CTCAE = 1;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Total lifetime;Disease control rate;Safety index; | — |
Countries
China
Contacts
Public ContactjianguoDong
Lankao First Hospital
Outcome results
None listed